BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32510138)

  • 21. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC).
    Tao L; Zhang L; Peng Y; Tao M; Li G; Xiu D; Yuan C; Ma C; Jiang B
    Oncotarget; 2016 Nov; 7(45):74314-74324. PubMed ID: 27494847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
    Chen Y; Yan H; Wang Y; Shi Y; Dai G
    Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
    Yin JB; Li N; Cui MM; Wang X; Wang RT
    BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.
    Garcea G; Ladwa N; Neal CP; Metcalfe MS; Dennison AR; Berry DP
    World J Surg; 2011 Apr; 35(4):868-72. PubMed ID: 21312035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma.
    Ueberroth BE; Khan A; Zhang KJ; Philip PA
    J Gastrointest Cancer; 2021 Mar; 52(1):160-168. PubMed ID: 32077005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
    Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
    Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Strong JS; Vos EL; Mcintyre CA; Chou JF; Gonen M; Tang LH; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Jarnagin WR; Drebin J; Kunstman JW; Allen PJ; Wei AC
    Am Surg; 2022 Jun; 88(6):1153-1158. PubMed ID: 33517697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
    Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
    Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
    Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
    Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis.
    Yang JJ; Hu ZG; Shi WX; Deng T; He SQ; Yuan SG
    World J Gastroenterol; 2015 Mar; 21(9):2807-15. PubMed ID: 25759553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
    Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma.
    Terasaki F; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Updates Surg; 2021 Feb; 73(1):251-259. PubMed ID: 32410163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
    Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
    J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
    Nurmi AM; Mustonen H; Haglund C; Seppänen H
    Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Markus M; Abendroth A; Noureddine R; Paul A; Breitenbuecher S; Virchow I; Schmid KW; Markus P; Schumacher B; Wiesweg M; Wendling J; Mende B; Siveke JT; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):579-591. PubMed ID: 32839836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
    Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
    Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of prognostic predictive model with neutrophil-lymphocyte ratio (NLR) in patients with gastric signet ring carcinoma.
    Yang S; Li S
    Medicine (Baltimore); 2022 Jan; 101(1):e28043. PubMed ID: 35029873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.